MedTrace Logo

Continuous Interscalene Blocks and Rebound Pain

NCT07770165 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2026-08-19

No results posted yet for this study

Summary

The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty.

Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale \[NRS\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."

Conditions

  • Total Shoulder Arthroplasty
  • Reverse Total Shoulder Arthroplasty
  • Interscalene Analgesia
  • Interscalene Blocks
  • Interscalene Nerve Block
  • Orthopedic Surgery Patients
  • Locoregional Anaesthesia
  • Rebound Pain

Interventions

DRUG

Continuous interscalene nerve block

This Interventional Group will receive a continuous interscalene block via a catheter for a duration of 48 hours with ropivacaine 0.2% at a fixed 5 mL/hour rate.

DRUG

Interscalene Block

This control group will receive a single shot interscalene block with 20 mL of ropivicaine 0.2%.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07770165 on ClinicalTrials.gov